MSC-derived microvesicles inhibit the progression of arthritis in a murine model of preclinical rheumatoid arthritis
Open Access
- 10 February 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1723572
Abstract
Objective: Preclinical rheumatoid arthritis (Pre-RA) represents a critical stage before the clinical manifestation of RA, characterized by autoimmune dysregulation. Early intervention in this stage can prevent the progression to full-blown RA. This study aimed to develop a robust murine model of Pre-RA and measure the therapeutic potential of mesenchymal stem cell-derived microvesicles (MSC-MVs) as a novel strategy to prevent the onset and progression of autoimmune arthritis. Methods: Low-concentration collagen emulsion was administered subcutaneously at the tail base on days 0 and 21 to establish the preclinical collagen-induced arthritis (Pre-CIA) model. Disease progression was assessed over 45 days based on CIA scoring, body weight monitoring, CT images, histopathology, laboratory tests, and flow cytometry. Pre-CIA mice were treated with MSC-MVs. The pharmacokinetic characteristics of MSC-MVs were measured using in vivo fluorescence imaging, and therapeutic efficacy was evaluated through CIA scoring, joint inflammation analysis, complementary imaging, and immunological assays. Results: We established a mouse model of Pre-CIA characterized by mild arthritis using reduced doses of immunizing agents. Pre-CIA mice were less likely to experience arthritis (59.09%) than CIA mice (95.45%). In addition, Pre-CIA mice exhibited gradual increases in CIA scores and increased histological damage, consistent with Pre-RA. LPS injection accelerated the rapid progression from Pre-CIA to CIA. Micro-CT revealed mild trabecular bone loss and joint erosion in Pre-CIA mice compared to severe damage in CIA mice. Histological staining demonstrated intermediate cartilage and bone damage in Pre-CIA mice, with significant synovial hyperplasia and cartilage loss. The serum levels of pro-inflammatory markers (IL-1β, TNF-α, IL-6, and CRP P<0.05) and RA-specific autoantibodies (anti-CII, and anti-CCP P<0.05) were upregulated in Pre-CIA mice. Flow cytometry revealed immune imbalances in Pre-CIA mice, with a decreased abundance of Tregs and Th2 cells and an increased abundance of Th1, Th17, and Tfh cells. Treatment with MVs prevented the progression of arthritis in Pre-CIA mice, reduced inflammatory marker levels, stabilized bone and cartilage integrity, and restored immune balance. Conclusions: The Pre-CIA model effectively reflects the key pathological and immunological features of Pre-RA, providing a robust platform for studying disease mechanisms and early therapeutic interventions. Treatment with MSC-MVs successfully showed reversal of pathological features, highlighting their potential as a novel therapeutic strategy for preventing the progression of Pre-RA to full-blown rheumatoid arthritis. These findings underscore the clinical significance of MSC-MVs in addressing unmet needs in the early management of RA.Keywords
This publication has 60 references indexed in Scilit:
- Efficacy and safety of mesenchymal stem cell-derived microvesicles in mouse inflammatory arthritisInternational Immunopharmacology, 2024
- Enhancers of mesenchymal stem cell stemness and therapeutic potencyBiomedicine & Pharmacotherapy, 2023
- Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individualsAutoimmunity Reviews, 2022
- Pre-RA: Can early diagnosis lead to prevention?Best Practice & Research Clinical Rheumatology, 2022
- The impact of airborne endotoxin exposure on rheumatoid arthritis-related joint damage, autoantigen expression, autoimmunity, and lung diseaseInternational Immunopharmacology, 2021
- The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritisAutoimmunity Reviews, 2021
- Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient PreferencesCurrent Rheumatology Reports, 2016
- Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated ReviewCurrent Rheumatology Reports, 2014
- Type II collagen autoimmunity in a mouse model of human rheumatoid arthritisAutoimmunity Reviews, 2007
- The K/BxN Mouse Model of Inflammatory Arthritis2007